Study to evaluate role of Ayurvedic drug Navayasa Churna in the treatment of Anemia

CLINICAL EVALUATION OF NAVAYASA CHURNA IN THE MANAGEMENT OF IRON DEFICIENCY ANAEMIA

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/08/009200

Enrollment

150

Registered

2017-08-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- CLINICAL EVALUATION OF NAVAYASA CHURNA IN THE MANAGEMENT OF IRON DEFICIENCY ANAEMIA

Interventions

Intervention1: CLINICAL EVALUATION OF NAVAYASA CHURNA IN THE MANAGEMENT OF IRON DEFICIENCY ANAEMIA: It consist of triphala,trikatu,vidang,mustak,chitraka,lauha bhasam Intervention2: NavayasaChurna: Na

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients of either sex aged between 18 to 50 years. 2) Patients with iron deficiency anaemia (Hb 8gm-10gm. %), 3) S. Ferritin 4) Patients with peripheral blood smear suggestive of Iron deficiency Anaemia 5) Willing and able to participate for 120 days.

Exclusion criteria

Exclusion criteria: 1. Patients suffering from Thalassemia major / Aplastic anaemia / Sickle cell anaemia. 2. Patients with evidence of malignancy. 3. Stool examination found with positive ova/cyst/parasite of worm infestation. 4. Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, Bleeding disorders, etc.) 5. Patients who have a past history of Atrial Fibrillation, Coronary Artery Disease (CAD), Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. 6. Symptomatic patient with clinical evidence of Heart failure. 7. Patients with poorly controlled Hypertension ( > 160 / 100 mm Hg) 8. Patients suffering from Diabetes Mellitus (F.B.S. > 250 mg/dl.) 9. Patients on prolonged ( > 6 weeks) medication with corticosteroids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study. 10. Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit), or Renal Disorders (defined as S. Creatinine >1.2mg/dL), Total Serum Cholesterol & / or Serum Triglycerides > 250 mg/dl, Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]). 11. Alcoholics and/or drug abusers. 12. Pregnant / lactating woman 13. H/o hypersensitivity to the trial drug or any of its ingredients. 14. Patients who have completed participation in any other clinical trial during the past six (06) months. 15. Any other condition which the Investigator thinks may jeopardize the study.

Design outcomes

Primary

Measure	Time frame
Change in Hb%Timepoint: Time frame :Baseline to on Day 15th / 30th / 45th / 60th / 75th / 90th and Follow up visit on 120th day	—

Secondary

Measure	Time frame
Symptomatic relief. Change in Serum ferritin level. Change in Peripheral Blood Smear Picture.Timepoint: Time Frame: at Baseline,at end of 90 days and 120 days	—

Countries

India

Contacts

Public ContactDr SKSharma

Ayurveda Regional Research Institute, Mandi HP

arri.mandi@gmail.com09418062731

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026